|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two scoring methods were used to convert the scores on the PHQ-9, GAD-7 and K6 to the PROMIS depression and anxiety metrics.
|
29872956 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like.
|
25106036 |
2014 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with PNES had higher self-reported anxiety and depression levels (GAD-7: p = 0.04, PHQ-9: p < 0.01; BDI-II: p < 0.01) but similar QOL to PWE (p = 0.78).
|
31759316 |
2020 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; <i>P</i>=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; <i>P</i>=0.91).
|
29025788 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prevalence estimates for depressive disorder (CIDI), depressive symptoms (BDI ≥ 16), anxiety symptoms (GAD-7 ≥ 10) and PTSD (PCL-C DSM criteria) were 3.8, 5.9, 3.6, and 4.5% respectively for twins and 3.9, 9.8, 5.1 and 5.4% for singletons.
|
29343229 |
2018 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations between non-disclosure and the following factors were established using modified Poisson regression with adjustment for socio-demographic factors (gender, age group, ethnicity), HIV-related factors (time since HIV diagnosis, ART status), and clinic: low social support (score ≤ 12 on modified Duke-UNC FSSQ); depression and anxiety symptoms (≥10 on PHQ-9 and GAD-7 respectively); self-reported ART non-adherence in past 2 weeks/3 months; VL non-suppression (clinic-recorded VL > 50 copies/mL among those who started ART ≥ 6 months ago).
|
27586375 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The response rate, as measured by a 50% decrease in scores, for those with initial scores ≥10 was 58.6% for depression (PHQ-9) and 50% for anxiety (GAD-7).
|
28165775 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A binary logistic regression analyses were conducted to test the association between all four ratings in GAD-7 (anxiety) and PHQ-9 (depression) scales subitems as covariates, and migraine vs no headache as the outcome.
|
28324317 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females.
|
22662185 |
2012 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> The study indicated that past-year Wave II financial mistreatment was associated with significantly increased likelihood of depression, PTSD, GAD, and poor self-rated health; and financial mistreatment perpetrated by family members was associated with particularly increased risk of depression.
|
29665715 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall findings suggest that the workbook format was no less effective or acceptable than the validated online format.Significant improvements (avg. improvement; Internet Group vs Workbook Group) in levels of disability (PDI: 16% vs 24%; RMDQ: 12% vs 15%), anxiety (GAD-7: 36% vs 26%), and depression (PHQ-9: 36% vs 36%) were observed in both groups immediately posttreatment.
|
28394850 |
2017 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas cortical GAD67 reduction and subsequent GABA level decrease are consistently observed in schizophrenia and depression, it remains unclear how these GABAergic abnormalities contribute to specific symptoms.
|
29362511 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mean post treatment PHQ-9 and GAD-7 scores remained above threshold for those receiving CBT_DA but not those receiving CBT-D.
|
30048513 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
For GAD age at onset, family history, biology and symptomatology are close to those of depression.
|
18344044 |
2008 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, self-rating questionnaires were used to assess somatic symptom severity (PHQ-15), depression severity (PHQ-9) and anxiety severity (GAD-7).
|
28554368 |
2017 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Primary outcomes included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.
|
28057609 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial.
|
28242498 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PWE from rural West China were evaluated for depression and anxiety with the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 (GAD-7; Chinese version).
|
30125939 |
2018 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The resulting groups were characterized with regard to Quality of Life (MacNew), anxiety and depression (GAD-7 and PHQ-9) and resilience (RS-13).
|
28006984 |
2017 |